- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04675931
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
An Adaptive, Randomized, Active-controlled, Open-label, Sequential Cohort, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Intravenous Cipargamin (KAE609) in Adult and Pediatric Participants With Severe Plasmodium Falciparum Malaria (KARISMA - KAE609's Role In Severe Malaria)
The purpose of this study is to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria.
The study also intends to evaluate clinical treatment success using a novel clinical endpoint for drug development in severe malaria.
Severe malaria is a medical emergency and is affecting primarily young children in Africa. Injectable artesunate is the standard of care for the treatment of severe malaria and is highly efficacious. However, the spread of artemisinin-resistance in Plasmodium falciparum in Asian countries poses a threat for future treatment of patients with this life-threatening disease. To mitigate this risk, there is a need of another drug in malaria endemic countries. Cipargamin treatment results in rapid clearance of parasites including artemisinin resistant parasites.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Study Locations
-
-
-
Burkina Faso, Burkina Faso, 2208
- Recruiting
- Novartis Investigative Site
-
Ouagadougou, Burkina Faso
- Recruiting
- Novartis Investigative Site
-
-
-
-
Democratic Republic Of Congo
-
Kinsasha, Democratic Republic Of Congo, Congo, The Democratic Republic of the, BP 7948
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Abidjan, Côte D'Ivoire, 13BP972
- Recruiting
- Novartis Investigative Site
-
Agboville, Côte D'Ivoire, BP 154
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Lambarene, Gabon, BP 242
- Recruiting
- Novartis Investigative Site
-
-
-
-
Chhattisgarh
-
Raipur, Chhattisgarh, India, 492099
- Recruiting
- Novartis Investigative Site
-
-
Gujrat
-
Surat, Gujrat, India, 395002
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Siaya, Kenya, 2300
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Ilorin, Nigeria, 240003
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Kigali, Rwanda, BP 4560
- Recruiting
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Cohort 1: Participants aged ≥ 12 years with moderately severe malaria as defined in (prostration and/or repeated vomiting) without presence of other signs of severe malaria (and with high P. falciparum parasitemia (60,000-250,000 parasites per µl)
- Subsequent Cohorts 2 to 5: Participants diagnosed with severe malaria as defined in modified version of WHO criteria and P. falciparum parasite count of ≥ 5000 per µl
- Cohort 2: Participants aged ≥ 12 years
- Cohort 3: Participants aged 6 - < 12 years
- Cohort 4: Participants aged 2 - < 6 years
- Cohort 5: Participants aged ≥ 6 months - < 2 years
Exclusion Criteria:
Exclusion criteria applying to all Cohorts 1 to 5:
- Mixed Plasmodium infections
- Treatment with quinine or artemisinin derivative or any other antimalarial drug or any antibiotic with known antimalarial activity within 12 hours of screening.
Signs/symptoms of severe malnutrition in general accordance with WHO guidelines:
- Under 18 years: <-3 Z-scores of WHO growth standard for weight-for-height/length (in children < 5 years) or BMI for age (5-18 years), or very low mid-upper arm circumference (MUAC < 115 mm in children < 12 years, < 160mm 12-18 years), or bilateral pitting edema
- Over 18 years: BMI < 16 kg/m2 or MUAC < 160mm or bilateral pitting edema
Known underlying illness, surgical or medical condition, which is not related to ongoing event of severe malaria and which might jeopardize the participant's health in case of participation in the study or which might alter the distribution, metabolism or excretion of study treatment. For example:
- neurological or neurodegenerative disorders,
- cardiac, renal, or hepatic disease, diabetes,
- epilepsy, cerebral palsy,
- known or suspected to be HIV-1 positive and/or receiving antiretroviral treatment
- malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
- known or suspected cases of active infections or concurrent febrile illness such as TB, Typhoid, COVID-19 etc.
Additional exclusion criteria are as follows:
Exclusion criteria for Cohort 1:
- ALT > 5 x the upper limit of normal range (ULN), regardless the level of total bilirubin
- Total bilirubin is > 3 mg/dL
- Body weight of < 35 kg or >75 kg
Exclusion criteria for Cohort 2:
- Body weight of < 35 kg or >75 kg
- Participants diagnosed as moderately severe malaria due to repeated vomiting without presence of any of the symptoms of severe malaria
Exclusion criteria for Cohorts 3 to 5:
- Body weight of < 5 kg
- Participants diagnosed as moderately severe malaria due to repeated vomiting without presence of any of the symptoms of severe malaria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IV KAE609 Dose regimen 1
Intravenous KAE609 (cipargamin) 20 mg
|
Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2). These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5.
Other Names:
|
Experimental: IV KAE609 Dose regimen 2
Intravenous KAE609 (cipargamin) 40 mg
|
Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2). These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5.
Other Names:
|
Experimental: IV KAE609 Dose regimen 3
Intravenous KAE609 (cipargamin) Dose regimen 3 (dose will be evaluated post Interim analysis from Cohort 1 and Cohort 2.
|
Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2). These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5.
Other Names:
|
Active Comparator: IV Artesunate
IV Artesunate 2.4 mg/kg (for participants weighing at least 20 kg) IV Artesunate 3 mg/kg (for participants weighing less than 20 kg)
|
Parenteral artesunate is the WHO recommended first line treatment for severe malaria.
Hence IV artesunate is used as comparator.
Also, this will be used as rescue medication for participants where IV KAE609 is not working.
Other Names:
|
Other: Coartem
Standard of care (Coartem) will be given to all participants for 3 days as part of treatment.
|
Oral Standard of Care
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum) at 12 hours
Time Frame: Day 1 (12 Hours)
|
A blood draw will be performed at each collection time point for parasitemia assessment.
|
Day 1 (12 Hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants achieving clinical success over time
Time Frame: Day 3 (48 Hours), Day 4 to Day 29
|
Clinical success is a composite endpoint based on following criterias:
|
Day 3 (48 Hours), Day 4 to Day 29
|
Percentage of participants with individual signs of severe malaria over time
Time Frame: Day 1 to Day 29
|
Individual signs of severe malaria over time will be monitored for the presence of the following signs of severe malaria during the entire study duration:
|
Day 1 to Day 29
|
Percentage of participants developing hemolysis (early and delayed) after treatment
Time Frame: Day 8 and Day 29
|
Development (early and delayed) of hemolysis after treatment are defined as follows: Early Hemolytic anemia is defined as 10% or greater decrease in hemoglobin levels and an increase of LDH levels to >390 U/L, or an increase of >= 10% above baseline occurring up to Day 8 of the study. Delayed hemolytic anemia might occur > 7 days after initiation of parenteral study drug (IV artesunate or IV cipargamin) during the study period. The event is characterized by a 10% or greater decrease in hemoglobin levels accompanied by increase of LDH levels to >390 U/L, or an increase of >= 10% compared to the values measured at Day 8 of the study. |
Day 8 and Day 29
|
Percentage of participants with neurological sequelae at Day 29
Time Frame: Day 29
|
Detailed neurological examination will be conducted and relevant medical history collected under the following categories to assess the extent of neurological signs and symptoms at baseline and to monitor the extent of neurological sequelae in follow-up visits:
|
Day 29
|
Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum)
Time Frame: Day 2 (24 hours), Day 3 (48 hours)
|
A blood draw will be performed at each collection time point for parasitemia assessment
|
Day 2 (24 hours), Day 3 (48 hours)
|
Time to parasite clearance (PCT)
Time Frame: Day 1 (12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
|
Parasite Clearance Time (PCT) is defined as the time from the first dose until the first total and continued disappearance of asexual parasite forms which remained at least a further 24 hours
|
Day 1 (12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
|
Time to fever clearance (FCT)
Time Frame: Day 1 (12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
|
Fever Clearance Time (FCT) is defined as the time from the first dose until the first time the axillary body temperature decreased below and remained below 37.5°C axillary or 38.0°C oral/tympanic/rectal for at least a further 24 hours.
|
Day 1 (12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
|
Percentage of participants achieving P. falciparum parasite reduction ratios (PRR) at 12, 24 and 48 hours
Time Frame: Day 1 (12 hours), Day 2 (24 hours) and Day 3 (48 hours)
|
PRR is defined as the ratio of asexual parasite at baseline divided by asexual parasite at post-baseline.
If the asexual parasite count at post-baseline is 0, the half value of detection limit will be used to calculate the ratio.
|
Day 1 (12 hours), Day 2 (24 hours) and Day 3 (48 hours)
|
Percentage of participants with recrudescence and reinfection
Time Frame: Day 29
|
Time to event (recrudescence or reinfection) will be calculated from the time of first study medication to the date of first event if a patient experiences the event and be censored at the time of last parasite assessment if a patient does not experience the event due to whatever reason. Reinfection is defined as appearance of asexual parasites after clearance of initial infection with a genotype different from those parasites present at baseline. Recrudescence is defined as appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at baseline. Reinfection and Recrudescence must be confirmed by PCR analysis. |
Day 29
|
Time to recover from prostration
Time Frame: Day 1 to Day 29
|
To assess recovery of participants as measured by time (days and hours) to discharge from hospital or recovery from prostration compared to baseline.
|
Day 1 to Day 29
|
Time to switch to oral therapy
Time Frame: Day 3 to Day 29
|
Time to switch participants from IV therapy to Coartem (standard of drug for oral therapy) will be analyzed.
|
Day 3 to Day 29
|
Time to discharge from hospital
Time Frame: Day 3 to Day 29
|
All participants will be hospitalized.
Time (Days and Hours) to discharge from hospital will be analyzed.
|
Day 3 to Day 29
|
Number of Participants impacted on safety and tolerability assessments
Time Frame: Day 1 to Day 29
|
Adverse events (AE), Serious Adverse events (SAEs) will be collected from first dosing, Death including whether in-hospital death and routine laboratory assessments will be done up to last follow-up visit or until the event has resolved to baseline grade or better or the event was assessed stable by the investigator or the participant was lost to follow-up or withdrew consent.
|
Day 1 to Day 29
|
Observed maximum plasma concentration (Cmax) of IV Cipargamin
Time Frame: Day 1 - Day 8
|
Blood samples will be collected for activity-based pharmacokinetics characterization.
Cmax will be listed and summarized using descriptive statistics.
|
Day 1 - Day 8
|
Time of maximum observed drug concentration occurrence (Tmax) of IV Cipargamin
Time Frame: Day 1 - Day 8
|
Blood samples will be collected for activity-based pharmacokinetics characterization.
Tmax will be listed and summarized using descriptive statistics.
|
Day 1 - Day 8
|
Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of IV Cipargamin
Time Frame: Day 1 - Day 8
|
Blood samples will be collected for activity-based pharmacokinetics characterization.
AUClast will be listed and summarized using descriptive statistics.
|
Day 1 - Day 8
|
Area under the concentration time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of IV Cipargamin
Time Frame: Day 1 - Day 8
|
Blood samples will be collected for activity-based pharmacokinetics characterization.
AUC(0-inf) will be listed and summarized using descriptive statistics.
|
Day 1 - Day 8
|
Area Under the plasma concentration-time Curve from the time 0 to the last observed quantifiable concentration (AUC(0-t)) of IV Cipargamin
Time Frame: Day 1 - Day 8
|
Blood samples will be collected for activity-based pharmacokinetics characterization.
AUC(0-t) will be listed and summarized using descriptive statistics.
|
Day 1 - Day 8
|
AUC(0-t) divided by the dose administered (AUC(0- t)/D) of IV Cipargamin
Time Frame: Day 1 - Day 8
|
Blood samples will be collected for activity-based pharmacokinetics characterization.
AUC(0-t)/D will be listed and summarized using descriptive statistics.
|
Day 1 - Day 8
|
Terminal elimination half life (T^1/2) of IV Cipargamin
Time Frame: Day 1 - Day 8
|
Blood samples will be collected for activity-based pharmacokinetics characterization.
The half-live will be listed and summarized using descriptive statistics.
|
Day 1 - Day 8
|
Total systemic clearance for intravenous administration (CL) of IV Cipargamin
Time Frame: Day 1 - Day 8
|
Blood samples will be collected for activity-based pharmacokinetics characterization.
CL will be listed and summarized using descriptive statistics.
|
Day 1 - Day 8
|
volume of distribution during the terminal phase following intravenous elimination (Vz) of IV Cipargamin
Time Frame: Day 1 - Day 8
|
Blood samples will be collected for activity-based pharmacokinetics characterization.
Vz will be listed and summarized using descriptive statistics.
|
Day 1 - Day 8
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Malaria, Falciparum
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Anthelmintics
- Schistosomicides
- Antiplatyhelmintic Agents
- Lumefantrine
- Artemether
- Artesunate
- Artemether, Lumefantrine Drug Combination
Other Study ID Numbers
- CKAE609B12201
- 217692/Z/19/Z (Other Grant/Funding Number: Wellcome Trust and EDCTP within the PAMAFRICA Grant)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Malaria
-
University of OxfordCompletedSevere Falciparum MalariaBangladesh
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome TrustSuspendedSevere Falciparum MalariaIndonesia
-
Institute of Tropical Medicine, BelgiumKU Leuven; Leiden University Medical Center; Barcelona Institute for Global Health and other collaboratorsRecruitingUncomplicated Malaria | Severe Malaria | Asyptomatic Plasmodium InfectionMozambique, Belgium, Burkina Faso
-
Dr Fabrice BRUNEELCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedMalaria | Severe MalariaMali
-
Makerere UniversityUnknown
-
University of OxfordUniversity of Kinshasa; Mahidol Oxford Tropical Medicine Research UnitCompletedSevere MalariaCongo, The Democratic Republic of the
-
Swiss Tropical & Public Health InstituteMakerere University; Kinshasa School of Public Health; Clinton Health Access... and other collaboratorsCompletedSevere MalariaCongo, The Democratic Republic of the, Nigeria, Uganda
-
Swiss Tropical & Public Health InstituteMedicines for Malaria VentureCompletedSevere MalariaCongo, The Democratic Republic of the
-
National Institute of Allergy and Infectious Diseases...CompletedMalaria | Severe Malaria | Antimalarial Drug ResistanceCambodia
Clinical Trials on KAE609
-
Novartis PharmaceuticalsCompletedCure RateVietnam, Thailand
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsWellcome TrustCompleted
-
Novartis PharmaceuticalsMedicine for Malaria VentureTerminatedPlasmodium Falciparum MalariaAustralia
-
Novartis PharmaceuticalsRecruitingUncomplicated Plasmodium Falciparum MalariaCôte D'Ivoire, Kenya, Ghana, Uganda
-
Novartis PharmaceuticalsSupported by Wellcome Trust via Grant # Grant Number 207813/Z/17/ZCompletedMalariaGabon, Ghana, Mali, Rwanda, Uganda
-
Central South UniversityRecruitingCommon Mental DisorderChina